Opioid

FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

News

For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...

Opioid Use Disorder in Pregnant and Postpartum People

31 May 2023

Washington, DC

United States

May 31, 2023, 03:00 PM (Washington, DC time)

Buprenorphine versus methadone for the treatment of opioid dependence

Scientific article

Summary Background Opioid dependence is associated with substantial health and social burdens, and opioid agonist treatment (OAT) is highly effective in improving multiple outcomes for people who receive this treatment. Methadone and...

International Conference on Opioids

6 July 2023

Stockholm

Sweden

The International Research Conference Aims and Objectives

The International Research Conference is a federated organization dedicated to bringing together a significant number of diverse scholarly events for presentation within the conference program.

Problematic opioid use in Ireland, 2015–2019

Book

In this report, the Health Research Board presents the results of a study that aimed to estimate the prevalence of problematic opioid use in Ireland from 2015 to 2019 using a four-source capture-recapture method. Key Findings: In total...

Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes

Scientific article

28 July 2022

Abstract Background Virtually delivered healthcare (telehealth, telemedicine) has the potential to reduce gaps in access to opioid agonist therapy (OAT). Barriers to accessing OAT such as lack of transportation, in-person induction...

The effects of opioid policy changes on transitions from prescription opioids to heroin, fentanyl and injection drug use: a qualitative analysis

Scientific article

21 July 2022

Background Beginning in the 1990s, non-medical use of prescription opioids (POs) became a major public health crisis. In response to rising rates of opioid dependence and fatal poisonings, measures were instituted to decrease the...

Assessing the feasibility, usability and acceptability of the MySafeRx platform among individuals in outpatient buprenorphine treatment: Lessons learned from a pilot randomized controlled trial

Scientific article

Abstract Background Increasing buprenorphine/naloxone (B/N) access for opioid use disorder (OUD) is essential yet ensuring adherence and preventing diversion remains challenging. This study examines the feasibility, usability, and...

Neurofeedback for opioid dependent patients in an outpatient setting: a pilot feasibility study

Scientific article

15 April 2022

Background When used in combination with other therapies for drug use disorders, neurofeedback (NF) has been classified as "probably effective," according to recent research in the community of people with opioid use disorder. Despite these...